Through this data, “DiaDexus” evidenced the efficacy of the PLAC test, a diagnostic tool measuring Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in plasma, which aids in gauging the risk of coronary heart disease and ischemic stroke. Here, PLA2G7 is linked to coronary artery disorder.